Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$0.70 ▼ -0.04
(-5.58%)
MKT CAP: $252.4M • VOL: 5.42M
52W L $1 52W H $3
ROARABLE / RQD
E • 25/100
PIOTROSKI
3 / 9
OCGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $4.4M | $4.1M | $6.0M |
| YoY Revenue Growth % | +8.8% | -32.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$62.9M | -$54.8M | -$65.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$68.0M | -$54.0M | -$63.0M |
| EBITDA (Normalized) | -$62.8M | -$52.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$57.0M | -$42.1M | -$62.1M |
| Capital Expenditures (CapEx) | $185.0K | $3.4M | — |
| Free Cash Flow (FCF) | -$57.1M | -$45.5M | -$62.1M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $18.6M | — | — |
| Total Debt (Short + Long Term) | $27.5M | $27.3M | — |
| Total Stockholders' Equity | -$12.2M | $29.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OCGN.